Daniel C. Scullin

1.4k total citations
23 papers, 1.1k citations indexed

About

Daniel C. Scullin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel C. Scullin has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Daniel C. Scullin's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Daniel C. Scullin is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Daniel C. Scullin collaborates with scholars based in United States. Daniel C. Scullin's co-authors include John D. Hainsworth, Howard A. Burris, F. Anthony Greco, Lisa H. Morrissey, Sharlene Litchy, Paul Richards, James D. Bearden, Denise A. Yardley, Steven Corso and Harvey Jay Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Daniel C. Scullin

20 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel C. Scullin United States 13 650 586 362 233 184 23 1.1k
Lisa H. Morrissey United States 14 768 1.2× 859 1.5× 372 1.0× 238 1.0× 179 1.0× 27 1.4k
Nidal M. Almasri Jordan 16 581 0.9× 439 0.7× 201 0.6× 83 0.4× 109 0.6× 41 947
Sharlene Litchy United States 15 1.2k 1.9× 1.0k 1.8× 749 2.1× 356 1.5× 322 1.8× 26 1.9k
Junhun Cho South Korea 23 568 0.9× 846 1.4× 103 0.3× 96 0.4× 284 1.5× 106 1.5k
Hans‐Heinrich Wacker Germany 18 782 1.2× 541 0.9× 325 0.9× 79 0.3× 499 2.7× 28 1.3k
Tipu Nazeer United States 20 364 0.6× 412 0.7× 100 0.3× 114 0.5× 35 0.2× 70 1.4k
Jee Sook Hahn South Korea 19 498 0.8× 531 0.9× 222 0.6× 31 0.1× 161 0.9× 57 1.2k
Masahiro Yokoyama Japan 15 575 0.9× 461 0.8× 325 0.9× 114 0.5× 185 1.0× 61 1.0k
Diane L. Pickering United States 16 490 0.8× 455 0.8× 235 0.6× 21 0.1× 82 0.4× 29 1.3k
Tycel Phillips United States 22 956 1.5× 899 1.5× 554 1.5× 142 0.6× 367 2.0× 149 1.6k

Countries citing papers authored by Daniel C. Scullin

Since Specialization
Citations

This map shows the geographic impact of Daniel C. Scullin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Scullin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Scullin more than expected).

Fields of papers citing papers by Daniel C. Scullin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Scullin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Scullin. The network helps show where Daniel C. Scullin may publish in the future.

Co-authorship network of co-authors of Daniel C. Scullin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel C. Scullin. A scholar is included among the top collaborators of Daniel C. Scullin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel C. Scullin. Daniel C. Scullin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scullin, Daniel C., et al.. (2024). Acute Graft versus Host Disease in a Lung Transplant Recipient. The Journal of Heart and Lung Transplantation. 43(4). S489–S490.
2.
Nellore, Anoma, et al.. (2024). TRIPLE COVERAGE FOR REFRACTORY MRSA PNEUMONIA WITH VV-ECMO RESCUE. CHEST Journal. 166(4). A1028–A1029.
3.
4.
Nellore, Anoma, Keith Wille, Daniel C. Scullin, et al.. (2022). Bilateral Lung Transplantation With Donor Positive for COVID-19 Infection on Bronchoalveolar Lavage: A Case Report. Transplantation Proceedings. 55(3). 540–542. 1 indexed citations
5.
Chiles, J.W., et al.. (2020). A REMARKABLE RESPONSE TO ANGIOTENSIN II THERAPY IN SEVERE SARS-COV-2 INFECTION. CHEST Journal. 158(4). A1012–A1012. 1 indexed citations
6.
Spigel, David R., John D. Hainsworth, Howard A. Burris, et al.. (2005). Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer. 7(2). 127–132. 25 indexed citations
7.
McKay, Charles, John D. Hainsworth, David R. Spigel, et al.. (2005). Adjuvant paclitaxel (P)/carboplatin (C) in stages I, II non-small cell lung cancer (NSCLC): Comparison of two schedules in phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(16_suppl). 7123–7123. 1 indexed citations
8.
Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (2003). Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 21(2). 193–199. 19 indexed citations
9.
Hainsworth, John D., Lisa H. Morrissey, Daniel C. Scullin, et al.. (2002). Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma. Cancer. 94(9). 2426–2433. 7 indexed citations
10.
Hainsworth, John D., Lisa H. Morrissey, Daniel C. Scullin, et al.. (2002). Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma. Cancer. 94(9). 2426–2433. 25 indexed citations
11.
Greco, F. Anthony, Howard A. Burris, Sharlene Litchy, et al.. (2002). Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 20(6). 1651–1656. 85 indexed citations
12.
Hainsworth, John D., Sharlene Litchy, Howard A. Burris, et al.. (2002). Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. 20(20). 4261–4267. 321 indexed citations
13.
14.
Burris, Howard A., John D. Hainsworth, Joan B. Erland, et al.. (2000). Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.. PubMed. 27(1 Suppl 2). 9–13. 12 indexed citations
15.
Hainsworth, John D., Howard A. Burris, Lisa H. Morrissey, et al.. (2000). Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 95(10). 3052–3056. 200 indexed citations
16.
Hainsworth, John D., Howard A. Burris, Lisa H. Morrissey, et al.. (2000). Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 95(10). 3052–3056. 182 indexed citations
17.
Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (1999). Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 85(6). 1269–1276. 35 indexed citations
18.
Saxman, Scott, et al.. (1991). Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Investigational New Drugs. 9(3). 253–256. 20 indexed citations
19.
Mandanas, Romeo A., et al.. (1991). Phase II Trial of Cimetidine in Metastatic Melanoma. American Journal of Clinical Oncology. 14(5). 397–399. 15 indexed citations
20.
Scullin, Daniel C. & Harvey Jay Cohen. (1979). Myelomatous pleural effusion: Clinical course and immunologic characterization of the pleural fluid cells. American Journal of Hematology. 6(3). 267–273. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa H. Morrissey Breakdown of academic impact, for papers by Nidal M. Almasri Breakdown of academic impact, for papers by Sharlene Litchy Breakdown of academic impact, for papers by Junhun Cho Breakdown of academic impact, for papers by Hans‐Heinrich Wacker Breakdown of academic impact, for papers by Tipu Nazeer Breakdown of academic impact, for papers by Jee Sook Hahn Breakdown of academic impact, for papers by Masahiro Yokoyama Breakdown of academic impact, for papers by Diane L. Pickering Breakdown of academic impact, for papers by Tycel Phillips
Rankless by CCL
2026